A phase III randomized double-blind placebo-controlled trial was conducted in the urban neighborhoods of Delhi to assess whether Oral Rotavirus Vaccine ROTAVAC ® interferes with the immune response to childhood vaccines when
Introduction
The World Health Organization (WHO) recommends the universal use of rotavirus vaccines in the national immunization programs of all regions of the world, due to the high disease burden especially in high child mortality settings [1] .
The scale up of rotavirus vaccines in developing countries is limited by inadequate availability of high quality vaccines at affordable prices. Currently, the rotavirus vaccines available are: RotaTeq ® (Merck) and Rotarix ® (GSK) vaccines. These We report the findings of a study conducted to determine whether three doses of ROTAVAC ® when co-administered with other childhood vaccines i.e. Oral Polio Vaccine (OPV) and Pentavalent Vaccine against Diphtheria, Pertussis, Tetanus (DPT), Hepatitis B (HepB) and Haemophilus influenza type b (Hib) interferes with their immune response. These data are needed for obtaining WHO prequalification, which will allow access and equitable use of the vaccine for children in lower income countries. The immunogenicity and safety of ROTAVAC ® and the clinical lot consistency of three production lots of ROTAVAC ® were also assessed. The results of the clinical lot consistency will be published separately.
Material and methods

Study design and participants
This phase III randomized double-blind placebo-controlled study was conducted between May 2014 and August 2015 in Delhi, India. The study was conducted in compliance with the protocol, Good Clinical Practices (GCP), Schedule Y and Ethical guidelines for biomedical research on human participants [7, 8] .
The study was approved by the Translational Health Science and Technology Institute (THSTI) Institutional Ethics Committee and the Western Institutional Review Board.
Study participants and procedures
This study was conducted in low resource urban neighborhoods in Delhi. The description of the site has been reported earlier [5] . Participants were identified through a household survey and infants were enrolled into the study after obtaining informed consent from the parents and screening the infant for eligibility. Infants between 42-55 days of age whose parents were willing to participate and had no plans of moving away were eligible for enrolment. Infants were excluded if they had already received the first dose of the childhood vaccines or any other rotavirus vaccine, had immunodeficiency disease or chronic gastroenteritis disease, and/or any condition warranting exclusion by the investigator. Infants were temporarily excluded if they had diarrhea or any illness requiring hospital referral on the day of screening.
Enrolled infants were given three doses of ROTAVAC ® or placebo along with childhood vaccines (OPV and Pentavalent vaccine) at 6-7 weeks, 10-<14 and 14-<18 weeks of age. A minimum interval of 4 weeks was maintained between two doses of ROTAVAC ® or placebo plus childhood vaccines. Infants also received 3. Laboratory assays
Assessment of immune response to childhood vaccines
Immune responses to childhood vaccines were assessed using standard criteria for seroprotective titers for anti-poliovirus (>1/8 dilution) [9, 10] Diphtheria toxoid (>0.1 IU/mL), tetanus toxoid (>0.1 IU/mL) [11] , HepB (≥10 mIU/mL) [12] and Hib (≥0.15mcg/mL) [11] and Geometric Mean Concentrations (GMC) for pertussis [11] . For determining polio antibody titer in serum, polio virus infectivity neutralization assay was performed at Enterovirus Research Centre, Mumbai.
Quantitative determination of antibodies against DPT and Hib was done using Enzyme linked Immuno-Sorbent Assay (ELISA) and quantitative determination of antibodies to HepB surface antigen (anti-HBs) was done using Microplate Enzyme Immuno Assay (MEIA) at SRL limited, Mumbai. Infants with signs and symptoms of suspected intussusception or illness requiring hospital referral were assessed and treated at the study clinic or at referral hospitals.
Assessment of immunogenicity of ROTAVAC
All cases of intussusception confirmed by the treating physician were reviewed by an independent case adjudication committee to ascertain if they met the Diagnostic Certainty Level Criteria 1 developed by Brighton Collaboration Intussusception
Working Group [14] .
Statistical analysis
The primary analysis population for the immunogenicity endpoints was the per protocol population defined as a subset of randomized subjects who received three doses of ROTAVAC ® /Placebo (any/all vaccine production lot) and childhood vaccines concomitantly (received the childhood vaccines on the same day as ROTAVAC ® /Placebo), with no major protocol deviations (impact the eligibility criteria or determined to potentially interfere with the immune responses to study vaccines). The analysis population for all safety endpoints was the safety population defined as all randomized subjects who received at least one dose of ROTAVAC ® /Placebo, with or without childhood vaccines, and had some safety data available.
The non interference of ROTAVAC
® with childhood vaccines were tested for formal statistical non-inferiority testing with pre-specified margins using the two sided 95% confidence interval (CI) for the difference between the two treatment groups. The non-inferiority margins are 10 percentage points for the seroprotection rates for polio types 2 and 3, Diphtheria toxoid, Tetanus toxoid, Hib anti-PRP antibodies, and Hepatitis B; 15 percentage points for polio type 1 seroprotection rate; and 2-fold for Pertussis GMC.
Seroprotection rates were analyzed using the two-sided 95% CI for the absolute rate difference (Placebo − ROTAVAC ® ) between the treatment groups. The twosided 95% CI for the seroprotection rates were estimated by a likelihood score method by Gart and Nam using NCSS software [15] . GMCs for Pertussis were analyzed using the two-sided 95% CI for the ratio of geometric mean titers (GMT) (Placebo/ROTAVAC ® ) between the treatment groups. Two-sided 95% CIs were estimated for the difference between means of log10 (concentration), under the assumption that log10 (concentration) is normally distributed, using the tdistribution. Antilogs of the log mean and the corresponding confidence limits were taken to obtain a ratio of GMCs and the CI.
Sample size assumptions were made considering all comparisons that were part of the primary childhood vaccine immune interference objective. 1356 infants were enrolled; 339 in each of the 4 randomization arms allowing for 15% and 20% loss to follow up and giving a power of 82% and 78%, respectively, for all comparisons simultaneously. Since the loss to follow-up was much lower than 20% and the observed seroprotection rates to all 3 polio types were much higher than estimated (60-80% planned vs. ≥90% observed), this study had much higher power than planned for all analyses.
Safety results were analyzed in the intention to treat population which included all infants who had received at least one dose of ROTAVAC ® or placebo with or without childhood vaccines. All events were coded using the Medical dictionary for Regulatory Activities (MedRA, Version 17.0). An independent Data and Safety
Monitoring Board conducted safety review of blinded and unblinded data analyses.
Statistical analysis was performed by DiagnoSearch Life Sciences Pvt. Ltd using SAS software version 9.2.
Role of funding sources
PATH, USA; provided funding. The funder had no influence on the implementation and data collection. Analysis was done by DiagnoSearch Life Sciences Pvt.
Ltd.
Results
Study subjects
Between 26 May 2014 and 17 September 2014, of the 1683 infants screened, 1356 infants were enrolled; 1017 were randomized to the ROTAVAC ® group and 339 to the placebo group. 1327 infants completed 1 year follow up (Fig. 1) . The age at first dose in both groups was mean (SD) 6.4 weeks (0.47) weeks. 1273 (93.9%) of the enrolled infants received 2 doses and 1244 (91%) received all three doses of ROTAVAC ® or placebo. The baseline characteristics in both the groups were similar (Table 1 ).
Immune response to childhood vaccines
Post vaccination, seroprotective level of antibodies against polio virus type 1, 2, and 3 were present in 98.2%, 99.4% and 92.4%, respectively, of infants receiving OPV with ROTAVAC ® , and in 99%, 98.3% and 92.7%, respectively, of infants receiving OPV with placebo. Difference in proportions that had titer ≥8 between these groups was 0.8% (95% CI −1.1%, 2.2%) for type1 strain, −1.2% (95% CI −3.3%, 0.2%) for type 2 strain and 0.3% (95% CI −3.5%, 3.6%) for type 3 polio virus strain (Table 2) . Almost all infants, irrespective of the treatment group, Article No~e00302 developed protective antibody titer against diphtheria toxoid, tetanus toxoid and Hib (anti-PRP antibodies). Over 93% developed protective titer against HepB (antiHBs antibodies). The difference in proportion of infants who developed protective antibody titers was 0.5% (95% CI −1.3%, 2.3%) for diphtheria toxoid, 0.9% (95% CI −0.3%, 2.4%) for tetanus toxoid, 2.2% (95% CI −1.7%, 6.0%) for anti-HBs antibodies and 0% (95% CI −1.3%, 1.1%) for anti-PRP antibodies. The ratio of GMCs between the placebo and ROTAVAC ® groups for pertussis toxin was 1.0 (0.8, 1.1) ( Table 2 ).
Immunogenicity
The proportion of infants who sero-converted with a ≥4 fold rise in the post both groups resulted in death. 5 deaths were reported during the follow up period and none of them were considered to be related to the vaccination. No case of intussusception meeting Diagnostic Certainty Level 1 criteria developed by Brighton Collaboration Intussusception Working Group was reported till 1 year of age (Table 4) .
Discussion and conclusions
The market for rotavirus vaccines is in its early stage of development, with two multinational vaccine manufacturers in positions to participate in this market. "N": number subjects in the PP population for each study group.
Percentage: Calculated based on number of subjects for which results are available (n).
4-fold responders: ≥4 fold rise in the RV-specific serum IgA antibody titers from baseline to 28 days post third dose. 3-fold responders: ≥3 fold rise in the RV-specific serum IgA antibody titers from baseline to 28 days post third dose.
2-fold responders: ≥2 fold rise in the RV-specific serum IgA antibody titers from baseline to 28 days post third dose.
The two-sided 95% CIs were estimated by a likelihood score method [Gart 1990 ] using NCSS software. CI for difference in antibody levels achieved against polio viruses, diphtheria toxoid, tetanus toxoid, HepB and Hib PRP was less than 10% and met the preestablished non-inferiority criteria, demonstrating non inferiority of antibody responses to these vaccines in the two study groups. The mean antibody level of antibody to pertussis between the two groups was not significantly different and the ratio of the GMC (placebo/ROTAVAC ® ) groups and the corresponding upper limit of the 95% CI was less than 2. The non inferiority of ROTAVAC ® group over placebo group with respect to concentration levels to pertussis toxin was established.
ROTAVAC ® is moderately immunogenic as measured by serum anti rotavirus
IgA. This immune response of 38.6% in the vaccine recipients is similar to 40.3% observed in the phase III efficacy trial [5] . SOC: System organ class.
n: Number of subject with events. Subject is counted only once per SOC or preferred term.
% Percentage is based on number of subjects in the Safety population for each study group (N).
E: Number of all reported events including multiple occurrences. * All 2 × 2 tables (proportion of subjects with at least one event in particular category) were compared using Fisher's exact test.
SAEs did not show any imbalances between the groups. Most of the AEs in this period were considered related to ROTAVAC ® or placebo, which is expected as a result of co-administration with routine childhood vaccines. The most common SAEs were lower respiratory tract infections and gastroenteritis.
Of the five deaths, all occurred among recipients of ROTAVAC ® ; none was judged related to ROTAVAC ® . Four of the deaths occurred between 79-141 days after ROTAVAC ® administration. One death which occurred 3 days after ROTAVAC ® vaccination was an unexplained sudden death.
No case of Intussusception was identified which met Brighton Level 1 criteria.
In conclusion, ROTAVAC ® can be safely co-administered with three doses of pentavalent vaccine and OPV without diminishing an infant's serum antibody responses to each component of these vaccines. It is also well tolerated when administered along with the routine childhood vaccines at 6, 10 and 14 weeks of age.
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